ArticleCureus2025
Neonatal Anemia in Preterm Infants: Are We Overtransfusing?
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS AND
objectivesThe purpose of this study was to ascertain the appropriate packed red blood cell transfusion (PRBCT) practice for preterm infants consistent with multiple international guidelines.
methodThis retrospective study was conducted at a tertiary care center in India from February 2019 to December 2020. All preterm neonates born at <32 weeks of gestation who received PRBCTs during the study period were included. The hemoglobin (Hb) levels at the time of transfusion were analyzed to assess adherence to the transfusion thresholds recommended by the British Committee for Standards in Haematology (BCSH), Canadian Blood Services (CBS), and the Australian National Blood Authority (ANBA), considering postnatal age and the need for respiratory support.
resultsA total of 43 preterm neonates (gestational age, 28.08±1.08 weeks; birth weight, 1,018±0.027 g) received 78 PRBCTs. Specifically, nine (11.5%) PRBCTs were given in the first week, 14 (18%) in the second week, and 55 (70.5%) at three or more weeks of age. Further, nine (11.5%) PRBCTs were given during mechanical ventilation (MV), 49 (63%) with non-invasive ventilation (NIV) or oxygen (O₂) support, and 20 (25.5%) without O₂ support. The appropriateness of all of the PRBCTs per the BCSH, CBS, and ANBA guidelines was 63/78 (80.7%), 58/78 (74.3%), and 78/78 (100%), respectively. Most of the neonates on respiratory support received PRBCTs in a manner consistent with the CBS, BCSH, and ANBA guidelines, whereas most of the neonates not on oxygen (O₂) therapy received PRBCTs for late anemia (at three weeks or more of age) at a higher Hb level than that suggested by the CBS and BCSH guidelines but consistent with the ANBA guidelines.
conclusionIn this transfusion audit study, liberal PRBCT practice was observed for late anemia among stable preterm infants, consistent with the CBS and BCSH blood transfusion guidelines. Hence, there is room for improvement in PRBCT policies in terms of quality-improvement interventions to prevent over-transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.